...Phase I trial showing that single doses of 0.15 to 5 mg/kg doses of IV TP-271...
...Society for Microbiology meeting in New Orleans. The trial is evaluating safety and pharmacokinetics of TP-271...
...of the synthetic fluorocycline antibiotic in healthy volunteers. Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH), Watertown, Mass. Product: TP-271...

...IV TP-271 in up to 56 healthy volunteers. Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH), Watertown, Mass. Product: TP-271...

...FDA granted Fast Track and Qualified Infectious Disease Product (QIDP) designations to IV TP-271 from Tetraphase...
...disease caused by bacterial biothreats and antibiotic-resistant pathogens. Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH), Watertown, Mass. Product: TP-271...

...In mice exposed to aerosolized anthrax, prophylactic intraperitoneal 3, 6, 12 and 18 mg/kg daily TP-271...
...daily for 21 days. In a treatment model, intraperitoneal 6, 12 and 18 mg/kg daily TP-271...
...the International Congress of Chemotherapy and Infection joint meeting in San Diego. Tetraphase is developing TP-271...

...In vitro, TP-271 demonstrated activity against major CABP pathogens, including Legionella pneumophila, Chlamydia pneumonia and Mycoplasma...
...CABP pathogens, including Legionella pneumophila, Chlamydia pneumonia and Mycoplasma pneumonia. The minimum inhibitory concentration of TP-271...
...at the European Congress of Clinical Microbiology and Infectious Diseases in Berlin. Tetraphase is developing TP-271...

...Infectious Diseases (NIAID) awarded the partners up to $36 million over five years to develop TP-271...

...CUBRC Inc. (Buffalo, N.Y.) will receive up to $35 million over five years to develop TP-271...